[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-330924-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-330924-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hypermethylated-tagme-as-a-universal-cancer-only-methylation-marker-and-its-application-in-diagnosis-and-recurrence-monitoring-of-urothelial-carcinoma","Hypermethylated TAGMe - as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma","","Urothelial carcinoma (UC) is the second most common urological malignancy, yet prior molecular markers have not delivered consistent clinical value for diagnosis and recurrence monitoring. TAGMe (TAG of Methylation) was developed by analyzing methylation levels in training tissue cohorts (n=567) and validated in an independent cohort (n=198). Detection used restriction enzyme-based bisulfite-free qPCR, with urine surveillance over six months.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hypermethylated-tagme-as-a-universal-cancer-only-methylation-marker-and-its-application-in-diagnosis-and-recurrence-monitoring-of-urothelial-carcinoma/330924/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hypermethylated-tagme-as-a-universal-cancer-only-methylation-marker-and-its-application-in-diagnosis-and-recurrence-monitoring-of-urothelial-carcinoma/330924.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is TAGMe and why is it important for urothelial carcinoma?","Question",{"text":63,"@type":64},"TAGMe is a methylation-based marker derived as a universal-cancer-only methylation indicator. It is investigated for improving UC diagnosis and recurrence monitoring with consistent clinical utility.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TAGMe measured in this study?",{"text":68,"@type":64},"TAGMe methylation was assessed using restriction enzyme-based bisulfite-free qPCR on tissue samples and urine samples collected during postoperative surveillance.",{"name":70,"@type":61,"acceptedAnswer":71},"How well did TAGMe distinguish UC from benign urinary diseases and what about recurrence timing?",{"text":72,"@type":64},"Hypermethylated TAGMe showed high sensitivity (88.9%) and specificity (90.0%) for distinguishing UC from benign urinary diseases. Abnormal TAGMe as a recurrence indicator may precede clinical recurrence by three months to one year.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},330924,1790125476,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Yang et al. Journal of Translational Medicine (2024) 22:608  \n[https://doi.org/10.1186/s12967-024-05420-3](https://doi.org/10.1186/s12967-024-05420-3)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nHypermethylated TAGMe  \nas a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma  \nZhicong Yang1†, Qing Chen2†, Shihua Dong1,3†, Peng Xu1,3†, Wanxiang Zheng4, Zhanrui Mao 1, Chengchen Qian3, Xiangyi Zheng3, Lihe Dai2, Chengyang Wang3, Haoqing Shi2, Jing Li5, Jianlin Yuan4*, Wenqiang Yu1* and Chuanliang Xu2,6*  \nAbstract  \nBackground Urothelial carcinoma (UC) is the second most common urological malignancy. Despite numerous molecular markers have been evaluated during the past decades, no urothelial markers for diagnosis and recurrence monitoring have shown consistent clinical utility.  \nMethods The methylation level of tissue samples from public database and clinical collected were analyzed. Patients with UC and benign diseases of the urinary system (BUD) were enrolled to establish TAGMe (TAG of Methylation) assessment in a training cohort (n = 567) using restriction enzyme-based bisulfite-free qPCR. The performance of TAGMe assessment was further verified in the validation cohort (n = 198) . Urine samples from 57 UC patients undergoing postoperative surveillance were collected monthly for six months after surgery to assess the TAGMe methylation.  \nResults We identified TAGMe as a potentially novel Universal-Cancer-Only Methylation (UCOM) marker was hypermethylated in multi-type cancers and investigated its application in UC. Restriction enzyme-based bisulfite-free qPCR was used for detection, and the results of which were consistent with gold standard pyrosequencing. Importantly, hypermethylated TAGMe showed excellent sensitivity of 88 . 9%(95% CI: 81 .4–94. 1%) and specificity of 90 . 0%(95% CI:  \n81.9–95. 3%) in efficiently distinguishing UC from BUD patients in urine and also performed well in different clinical scenarios of UC. Moreover, the abnormality ofTAGMe as an indicator of recurrence might precede clinical recurrence by three months to one year, which provided an invaluable time window for timely and effective intervention to prevent UC upstaging.  \n†Zhicong Yang, Qing Chen, Shihua Dong and Peng Xu have contributed equally to this work.  \n*Correspondence:  \nJianlin Yuan [jianliny@fmmu.edu.cn](jianliny@fmmu.edu.cn)[ ](jianliny@fmmu.edu.cn)Wenqiang Yu [wenqiangyu@fudan.edu.cn](wenqiangyu@fudan.edu.cn)[ ](wenqiangyu@fudan.edu.cn)Chuanliang Xu [chuanliang_xu@126.com](chuanliang_xu@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativeco](http://creativeco)[mmons.org/publicdomain/zero/1.0/](mmons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless o","cbCaibG5nGIXOuxF","https://ap.wps.com/l/cbCaibG5nGIXOuxF","pdf",3507088,12,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Trial registration","[{\"question\":\"What is TAGMe and why is it important for urothelial carcinoma?\",\"answer\":\"TAGMe is a methylation-based marker derived as a universal-cancer-only methylation indicator. It is investigated for improving UC diagnosis and recurrence monitoring with consistent clinical utility.\"},{\"question\":\"How was TAGMe measured in this study?\",\"answer\":\"TAGMe methylation was assessed using restriction enzyme-based bisulfite-free qPCR on tissue samples and urine samples collected during postoperative surveillance.\"},{\"question\":\"How well did TAGMe distinguish UC from benign urinary diseases and what about recurrence timing?\",\"answer\":\"Hypermethylated TAGMe showed high sensitivity (88.9%) and specificity (90.0%) for distinguishing UC from benign urinary diseases. Abnormal TAGMe as a recurrence indicator may precede clinical recurrence by three months to one year.\"}]","Hypermethylated TAGMe - as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma | PDF",1789990727]